Elacestrant
Menarini
['bcsm', 'emerald', 'elacestrant', 'breast']
findings from a subgroup analysis of the phase 3 emerald trial demonstrated elacestrant elicited prolonged pfs vs soc in er+, her2 non-detected esr1 mutated breast cancer who experienced disease progression. #asco23 #bcsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.